CytomX Therapeutics to Present at the Jefferies Healthcare Conference
01 Junio 2023 - 3:05PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
Sean McCarthy, D.Phil., chief executive officer and chairman, will
present at the Jefferies Healthcare Conference on Thursday, June 8
at 4:00 p.m. ET.
A live webcast of the fireside chat will be available on the
Events and Presentations page of CytomX’s website at
www.cytomx.com. In addition, management will be available for
one-on-one meetings with investors who are registered to attend the
conferences.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated biologics localized to
the tumor microenvironment. By pioneering a novel class of
conditionally activated biologics, powered by its Probody®
technology platform, CytomX’s goal is to transcend the limits of
current cancer treatments. CytomX’s robust and differentiated
pipeline comprises therapeutic candidates across multiple treatment
modalities including antibody-drug conjugates (“ADCs”), T-cell
engaging bispecific antibodies (“TCBs”), and immune modulators such
as cytokines and checkpoint inhibitors (“CPIs”). CX-2029 is an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD71. CytomX’s clinical pipeline also
includes cancer immunotherapeutic candidates against validated
targets such as the CTLA-4-targeting Probody therapeutic
BMS-986288, partnered with Bristol Myers Squibb, as well as
CX-904, a conditionally activated T-cell-engaging bispecific
antibody targeting the epidermal growth factor receptor (EGFR) on
tumor cells and the CD3 receptor on T cells, which is partnered
with Amgen. In addition, CytomX has a diverse preclinical portfolio
of wholly-owned assets including CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. CytomX has also established
strategic collaborations with multiple leaders in oncology,
including Amgen, Astellas, Bristol Myers Squibb, Regeneron and
Moderna. For more information about CytomX and how it is working to
make conditionally activated treatments the new standard-of-care in
the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024